Preemption In Pharmaceutical Cases: 2018 In Review

Law360 (January 7, 2019, 2:48 PM EST) -- 2018 marked another interesting year in the shifting landscape of pharmaceutical drug preemption cases and set the table for additional significant developments in 2019. A few opinions that caught our eye, and next year's forecast, are discussed below.[1]

Newly Acquired Information

In August 2018, the Seventh Circuit reversed a $3 million judgment following a plaintiff verdict in an Illinois innovator liability suicide case, arising from the decedent's ingestion of a generic form of the anti-depressant Paxil.[2] The court side-stepped a decision on the continued viability of innovator liability in Illinois, instead holding that innovator liability did not need to be reached...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!